SCHEMBL17546313

SCHEMBL17546313

CC1CCN(C(=O)c2ncccn2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.57
APOBEC3A P31941 1/20 0.53
APOBEC3G Q9HC16 1/20 0.53
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
GRM5 P41594 2/20 0.48
KMT2A Q03164 1/20 0.48
HPGD P15428 6/20 0.47
ALDH1A1 P00352 3/20 0.47
TP53 P04637 1/20 0.47
CTSB P07858 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
GAA P10253 1/20 0.45
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20007071 0.82 APOBEC3A (0.40) ACHEAPOBEC3AAPOBEC3GHPGDALDH1A1
SCHEMBL17540495 0.81 CHRM2 (0.41) ACHEAPOBEC3AAPOBEC3GALDH1A1CTSB
SCHEMBL21431294 0.81 AKR1C3 (0.43) ACHEKMT2A
SCHEMBL13744784 0.80 L3MBTL1 (0.73) ACHENPC1RAB9AHPGDALDH1A1
SCHEMBL28474171 0.79 CHRM2 (0.42) ACHEAPOBEC3AAPOBEC3GALDH1A1KDM4E
SCHEMBL968638 0.79 L3MBTL1 (0.50) NPC1HPGDALDH1A1TP53GAA
SCHEMBL19960615 0.78 HRH4 (0.52) NPC1RAB9AGRM5KMT2AHPGD
SCHEMBL15070488 0.78 ACHE (0.53) ACHEAPOBEC3AAPOBEC3GNPC1RAB9A
SCHEMBL969811 0.77 HPGD (0.52) NPC1HPGDALDH1A1TP53GAA
SCHEMBL22840310 0.77 KDM4E (0.56) ACHEAPOBEC3AAPOBEC3GNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753397-B2 Cereblon binders for the degradation of ikaros C4 THERAPEUTICS, INC. (US) 2023-09-12 US disclosed
US-20210009559-A1 CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS C4 THERAPEUTICS, INC. (US) 2021-01-14 US disclosed
US-20200039960-A1 RORC2 INHIBITORS AND METHODS OF USE THEREOF PFIZER INC. (US) 2020-02-06 US disclosed
EP-3428160-A1 HETEROBICYCLOARYL RORC2 INHIBITORS AND METHODS OF USE THEREOF Pfizer Inc (US) 2019-01-16 EP disclosed
US-20170233371-A1 RORC2 INHIBITORS AND METHODS OF USE THEREOF PFIZER INC. (US) 2017-08-17 US disclosed
US-20160046597-A1 RORC2 INHIBITORS AND METHODS OF USE THEREOF PFIZER (US) 2016-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200039960-A1 RORC2 INHIBITORS AND METHODS OF USE THEREOF RORC, RORB, RORA ACHE 4376/4885APOBEC3A 4433/4885APOBEC3G 4139/4885
US-20160046597-A1 RORC2 INHIBITORS AND METHODS OF USE THEREOF RORC, RORB, RORA ACHE 4376/4885APOBEC3A 4433/4885APOBEC3G 4139/4885
US-11753397-B2 Cereblon binders for the degradation of ikaros CRBN, IKZF1, IKZF3 ACHE 3575/4885APOBEC3A 853/4885APOBEC3G 932/4885
US-20210009559-A1 CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS CRBN, IKZF1, IKZF3 ACHE 2387/4885APOBEC3A 487/4885APOBEC3G 463/4885
US-20170233371-A1 RORC2 INHIBITORS AND METHODS OF USE THEREOF RORC, RORB, RORA ACHE 4376/4885APOBEC3A 4433/4885APOBEC3G 4139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.